Connect with us

Cannabis News

White House Raises Alarm About ‘High-Potency’ Marijuana And Its Marketing In New National Drug Strategy

Published

on

The White House released a new National Drug Control Strategy on Monday that raises the alarm about “high-potency” marijuana and expresses concern that international cartels and criminal groups are “exploiting” state cannabis laws. It also discusses the federal recriminalization of THC hemp products, which is planned for later this year under a law signed by President Donald Trump.

The publication of the new 195-page document by the White House’s Office of National Drug Control Policy (ONDCP) comes after a few weeks. The Trump administration announced that it is moving forward with a plan to reschedule marijuana according to the federal law, it does not mention this reform.

Instead, sections on cannabis focus largely on concerns about health effects and commercialization as more states implement legalization.

“The marketing of addictive substances poses a significant threat to the health of young people. Legal does not mean safe, and the industries that sell nicotine, alcohol, marijuana and psychedelics have adopted strategies similar to Big Tobacco’s historical targeting of young audiences,” the ONDCP strategy states.

“The commercialization of marijuana plays a role in normalizing use, increasing access and reducing the perception of harm risk among young people,” he says. “Marijuana products today are of unprecedented potency, often highly processed, aggressively advertised and often packaged to appeal to minors.”

The White House document also states that “converging evidence from multiple sources suggests that cannabis exposure increases the risk of psychosis, and that preventing marijuana use may serve to reduce the prevalence of psychosis, in addition to reducing cannabis use disorder and other consequences.”

It also “talks about young adults with great potential whose futures were stolen by drug-induced psychosis and high-potency marijuana-related suicides.”

“Despite the different legal status of marijuana in the United States, there are still Americans who suffer from addiction and side effects of marijuana and related products, such as psychoactive hemp derivatives or other high-THC products, and they deserve help. People who are addicted to marijuana may not realize that withdrawal can cause insomnia and anxiety, rather than treating drug-induced symptoms effectively. Psychosis, if diagnosed and treated early, schizophrenia or mitigates the potential impact on the progression of another serious mental illness, also known as scromiting, due to screaming and vomiting, is a common condition related to long-term marijuana and addiction and currently there are no drugs approved by the FDA such as marijuana addiction or withdrawal However, there is help for those who want it, and the tools to quit marijuana addiction should be made more accessible.

“While all drugs carry some degree of risk, marijuana has the highest conversion rate from psychosis to schizophrenia and bipolar disorder,” says Trump’s ONDCP. “Drug use is also associated with suicide, and marijuana was the number one drug found in toxicology reports of people who died by suicide under the age of 25 in Colorado and San Diego, more than alcohol or any other drug.”

“It is important that consumers are made aware of the health risks associated with marijuana use, including damage to heart health, cognition, and cancer. In a California study, from 2005 to 2019, cannabis-related diagnoses in emergency department visits increased by 1,800% for seniors 65 and older. Additionally, research indicates that marijuana can contain fungi that cause serious and often fatal infections and immunosuppressants. in people with conditions such as cancer, transplantation or HIV infection.

The document states that “marijuana smoking rates in the United States have surpassed tobacco use” and that “marijuana addiction or cannabis use disorder affected 20.6 million, or 7.1 percent, of Americans age 12 and older in 2024, and is the leading reason for seeking addiction treatment for those under 20.”

“According to the 2024 National Survey on Drug Use and Health (NSDUH), in 2024, for the first time, the number of Americans suffering from a drug use disorder exceeded the number suffering from an alcohol use disorder. This change has been driven primarily by the increase in marijuana use and addiction rates. We need to ensure that Americans who want marijuana are a tool and addiction. Withdrawals.”

Although Trump approved an initiative to legalize marijuana that appeared on the ballot in Florida in 2024, the administration’s document raises the alarm about “transnational criminal gangs that transport, store and sell illegal drugs in American communities, including interstate distribution of illegal drugs.”

Of particular concern are China-linked groups that “exploit state marijuana laws to establish large networks of illegal cultivation and interstate distribution,” the ONDCP said.

“The marijuana trade in the U.S. is no longer a low-level, scattered problem; it has been co-opted and industrialized by sophisticated, transnational criminal organizations, especially those with ties to China. These groups systematically exploit states where marijuana has been legalized under state law, taking advantage of these lax markets and regulations to establish a massive, unlicensed Oklahoma cultivation operation. Chinese criminal gangs operate more than 80% of the state’s thousands of marijuana and hemp farms. Scale it is terrible: in 2023, the state’s marijuana production exceeded the authorized medical requirement by at least 32 times, and 85.5 million plants remain unconsumed. These operations to supply the national black market for local marijuana consumption are not only the focus of agricultural crime, the trafficking of exploited workers, sophisticated money laundering and the use of dangerous pesticides that threaten public health and the environment.

The White House drug strategy also discusses hemp products at length.

Hemp derivatives with less than 0.3 percent delta-9 THC by dry weight were made federally legal under the 2018 Farm Bill signed by Trump during his first term. But late last year, the president signed new legislation containing provisions that will redefine hemp so that only products with a total of 0.4 milligrams of THC per container will be legal starting November 12th.

“The administration has been given new legislative authority to address certain psychoactive hemp-derived cannabidiol substances through the “hemp loophole closure” passed as part of the Agriculture, Rural Development, Food and Drug Administration, and Adopted Agencies Act funding bill for fiscal year (FY) 2026,” ONDCP said. the document says, “Closing these domestic sources of harmful substances is critical to degrading the overall availability of illegal drugs in our communities.”

“Psychoactive derivatives of hemp are a growing concern. Although the hemp plant itself contains small amounts of cannabinoids, such as delta-8 THC, delta-10 THC, THC-O-acetate, THCP, and other THC analogs, they are often produced in laboratories, and the latest products in the 2018 Farm Bill have proliferated. Containing these chemicals will be considered controlled chemicals under the Hemp Restriction Regulations, which take effect in November 2026. these are often sold in smoke shops and gas stations, are not regulated and may contain dangerous chemicals or psychoactive substances. In many cases of psychosis and suicide attempts, according to international conventions, cannabinoids are considered Schedule I drugs, and some states have banned these potentially dangerous products.

They say law enforcement will “increase efforts to prosecute the illegal production and distribution of dangerous substances originating in the United States,” including “targeting retail operations, such as vape and smoke shops, that illegally market harmful products, particularly to minors.”

In the meantime Trump recently asked Congress to take action to change the language of the hemp cannabinoid ban signed the law to allow sales of full-spectrum CBD products to continue, it is unclear how much he wants to reduce the scope of the scheduled federal restrictions and what kind of revised THC rules and limits he would prefer to sign into law.

Meanwhile, the ONDCP says the administration will “work to improve drug testing in clinical settings,” noting that “currently used hospital tests do not detect nitazene, psilocybin, or psychoactive hemp products such as delta-8 THC, and may not detect all fentanyl analogs.”

ONDCP Director Sara Carter Bailey has before expressed his support for medical cannabis, while stating that he has “no problem” with legalizationeven if you may not personally agree with the policy.

“I have no problem if it is legalized and controlled,” he said in 2024. “I mean, I may have my own issues about how I feel about it, but I think it’s a great way to treat cannabis for medicinal and medical reasons – especially for people with cancer and other diseases, you know – to treat the side effects of those diseases and illnesses and not the medicine. Saying we should make it illegal.”

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Ora Pharm affirms uninterrupted access to Helius products

Published

on

By

Ora Pharm has confirmed that New Zealand patients, prescribers and pharmacies continue to have uninterrupted access to Helius Therapeutics products following the successful acquisition of the business and its key assets, directly challenging the misinformation being circulated to patients and prescribers by cannabis importer MW Pharma Limited (trading as NUBU).

Industry monitoring was highlighted on Monday, July 20th, when Helius Therapeutics announced that NZ Grow Co. As he inaugurated Growers Day. The event demonstrated the full operational strength, advanced capabilities and integrated supply chain now fully operational under Ora Pharm’s leadership to support the growth of the NZ sector.

At the event, CEO Zoë Reece addressed concerns stemming from a July 9 industry bulletin distributed by NUBU, which stated that “Helius Therapeutics has ceased production and all products are now discontinued.”

© Ora Pharm

Ora Pharm said the statement was incorrect and had the potential to create unnecessary uncertainty in a highly regulated healthcare sector.

“Inaccurate information about the availability of medicines can cause unnecessary worry for patients, prescribers and pharmacies, interfere with treatment decisions and undermine confidence in the New Zealand cannabis industry.”

Ora Pharm completed the business and acquisition of key assets of Helius Therapeutics on June 18, 2026, resuming manufacturing, packaging and nationwide distribution the following day. All Helius brand formulated products and locally grown products remain approved and available for patient supply.

CEO Zoë Reece said the company’s focus is on ensuring continuity of care while strengthening New Zealand’s medicinal cannabis industry.

“The Helius facility gives New Zealand growers direct access to world-class pharmaceutical drying, extraction and manufacturing capabilities. Combined with NZ Grow Co., we are creating a secure and integrated pathway from cultivation to finished products and international markets. Our focus is on clinical continuity, quality assurance and confidence in patients and prescribing physicians every day.”

© Ora Pharm

The integration of the GMP-certified Auckland manufacturing facility with NZ Grow Co.’s cultivation network creates New Zealand’s largest medicinal cannabis supply chain. This unified network insulates domestic patients from volatile international import dependencies while providing independent local growers with a transparent, high-standard route to export markets.

Ora Pharm remains committed to working collaboratively across the sector to support patient access, strengthen confidence in the New Zealand cannabis industry and continue to invest in New Zealand’s pharmaceutical manufacturing capacity.

For more information:
Ora Pharm
(email protected)
www.orapharm.co.nz

Continue Reading

Cannabis News

California Treasurer Announces Hearing On Marijuana Business Banking Access Issues

Published

on

By

California’s state treasurer has announced he will convene a hearing next week to highlight the marijuana industry’s banking access “challenges” and its impact on businesses, workers and communities.

The hearing, organized by Treasurer Fiona Ma (D), comes ten years after her predecessor launched a Cannabis Bank Task Force to look into the issue.

Titled “Continuing the Conversation: Advancing Safe and Legal Banking for California’s Cannabis Industry,” Wednesday’s hearing will feature state and local officials, financial institutions and representatives of marijuana companies. The plan is to “review progress made, discuss remaining obstacles, and consider practical steps California can take to support a safe, transparent and well-regulated legal cannabis market,” Ma’s office said in a press release.

“Nearly a decade after the launch of the Cannabis Banking Working Group, California’s legal cannabis industry continues to face barriers to access to affordable and reliable financial services due to state-federal conflict,” Ma. he said. “This hearing it will help us assess what has changed, identify challenges that remain, and continue the conversation about practical solutions that support public safety, transparency, and responsible business operations.”

Last month, bipartisan members of the US House and Senate reintroduced the legislation protect banks from being penalized for providing financial services to marijuana businesses.

Previous iterations of the banking legislation have been introduced in previous sessions of Congress, and while the House of Representatives has passed versions on several occasions, the reform has never become law.

While some banks serve marijuana businesses, the continued federal illegalization of the plant has made many reluctant to work with the industry.

“Limited access may increase operating costs, complicate routine financial transactions, and require some businesses to handle larger amounts of money, creating additional security and administrative concerns,” Ma’s office said.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Peat is a lot more sustainable than we think

Published

on

By

Increasing public scrutiny has questioned whether the use of peat is environmentally sustainable. A new review According to Dr. James Altland, research director of the USDA’s Agricultural Research Service, and Dr. Bruce Bugbee of Utah State University, they present a more nuanced picture than much of the current evidence portrays.

“Much of the debate in the popular press suggests that the use of peat in horticulture is unsustainable because it causes global warming and other environmental impacts,” shares James. “We have seen that agriculture is much more sustainable than some parties in the media want us to believe.”

© USDA

Differences between regions matter
The review states that assessments of peatland sustainability should differentiate between regions. While European peatlands have been heavily impacted by centuries of drainage and peat extraction, most Canadian peatlands remain undisturbed, with only a small proportion used for horticulture. According to the authors, this distinction is important when assessing the environmental impact of peat production.

“Currently, Canadian peatlands are sequestering carbon faster than the rate of extraction from container crop production. At current rates of extraction and with appropriate restoration, peatland use in North America is environmentally sustainable.”

The authors note that horticultural peat extraction in Canada accounts for only a small fraction of the total peatland area and that harvested sites are routinely restored after production.

© USDA

Restoration supports long-term recovery
The paper highlights the role of restoration practices, particularly the Moss Layer Transfer Technique (MLTT), in restoring peat-forming ecosystems.

“Restoration techniques, such as the moss layer transfer technique, can turn harvested peatlands into carbon sinks over decades,” he added. The review found that restored peatlands can restore vegetation, biodiversity and carbon sequestration functions over time, while improvements in water storage and hydrological performance are also documented.

© USDA

Alternatives also have environmental impacts
The researchers also looked at published life cycle assessments comparing them to substrates such as peat, korea, wood fiber, perlite and rock wool. “Life cycle assessments show that alternative substrates often have environmental impacts comparable to or greater than peat, especially when considering water use, transport and fertilizer inputs.”

The review concludes that comparisons depend on system limitations and assumptions, and that broad claims that alternatives are inherently more sustainable than peat are not consistently supported by published analyses.

© USDA
Figure A: Global carbon storage in natural systems (Gt, gigatons)
(Hirschler and Osterburg, 2022; Cleary et al, 2005; IPCC, 2023)

Performance remains an important consideration
Beyond sustainability, the paper reviews the functional characteristics that have made peat the reference substrate for container production.

“Soil’s high cation exchange capacity, water retention and stability support optimal plant growth and nutrient uptake,” shares James. The authors point out that these properties contribute to efficient irrigation and fertilizer management, maintaining good root zone conditions.

Although wood fibers, coir, and other materials can reduce peat use in mixes, each introduces its own management considerations, such as nutrient immobilization, water use, or processing requirements.

© USDA
Figure B: Annual carbon flux from human activities and sequestration through natural processes (Gt CO2-eq per year)
(Hirschler and Osterburg, 2022; Cleary et al, 2005; IPCC, 2023)

Managing future demand
As the global demand for soilless growth media is expected to increase significantly in the coming decades, the authors believe that a variety of substrate materials will be required.

“At current rates of extraction and with appropriate restoration, peat use in North America is environmentally sustainable and remains essential for horticulture and urban greening.”

For more information:
US Department of Agriculture
James Altland, Head of Research
Application Technologies Research Unit
(email protected)
www.usda.gov

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media